@article{ATM10856,
author = {Emanuele Zaffuto and Pierre I. Karakiewicz and Umberto Capitanio},
title = {Complete response after treatment with first-line targeted anti-vascular endothelial growth factor therapy in metastatic renal cancer: what next?},
journal = {Annals of Translational Medicine},
volume = {4},
number = {15},
year = {2016},
keywords = {},
abstract = {In a recent issue of European Urology, Buchler et al. (1) reported population-based results from a cohort of patients who achieved complete response (CR) after treatment with first-line targeted anti-vascular endothelial growth factor (VEGF) therapy. From the initial cohort of 2,803 patients, 100 individuals achieving CR were identified (3.6%). The median time from treatment initiation to CR was 10.1 months. Median progression-free survival (PFS) from therapy initiation was 3.8 years (95% CI: 2.9–4.6 years) and the 5-year overall survival (OS) was 80% (95% CI: 70%–91%). There was no statistically-significant difference in survival rates between patients continuing or discontinuing treatment after achieving CR.},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/10856}
}